Compare BPC-157 and NAD+: molecular weight, CAS numbers, synthesis route, assay wavelengths, degradation pathways, counterions, and per-gram cost.
BPC-157 and NAD+ are not competing purchases — they are two different classes of reference material that happen to share a search box. BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV, monoisotopic mass ~1418.7 Da, average ~1419.5 Da, CAS 137525-51-0) produced by solid-phase peptide synthesis and shipped as a trifluoroacetate or acetate salt. NAD+ is a small-molecule dinucleotide (C₂₁H₂₇N₇O₁₄P₂, 663.43 g/mol, CAS 53-84-9) produced by fermentation or enzymatic synthesis. They are quantified at different wavelengths, degrade by different chemistry, carry different counterion problems, and differ in bulk price by three to four orders of magnitude per gram. A procurement decision between them is really a decision about which analytical package your protocol requires.
A defensible COA for a synthetic peptide and a defensible COA for a nucleotide cofactor are not the same document, and a supplier who hands you the same template for both has not done the work.
For BPC-157, the minimum credible package is:
For NAD+, the package looks different:
The single most common procurement error is treating "98% purity" as a portable claim. On a peptide it means 98% of integrated peak area at 214 nm. On NAD+ it may mean 98% by HPLC at 260 nm, or 98% by enzymatic assay, and those two numbers routinely disagree by 2–5 percentage points on the same lot because they measure different things. Our approach to documenting these separately is described on the quality page.
BPC-157 contains no tryptophan, no tyrosine, and no phenylalanine. It has no aromatic chromophore at all. The practical consequence: you cannot quantify BPC-157 by A280. Any protocol that assumes a Nanodrop reading will give a concentration is wrong for this sequence. Detection depends on the amide bond at 214 nm, where the extinction is low, mobile-phase absorbance is high, and the achievable signal-to-noise is materially worse than a 260 nm nucleotide method. Injection volume and column condition matter more here than they do for NAD+.
NAD+ is the opposite case. The adenine ring gives a strong, well-characterized 260 nm band, so a single spectrophotometer reading gives a concentration good to a few percent, and the 260/340 ratio flags reduced-form contamination in one measurement. That analytical convenience is a real, quantifiable procurement advantage: verifying a NAD+ lot in-house costs roughly one cuvette and five minutes, while verifying a BPC-157 lot means an HPLC run and, ideally, a mass spectrum.
Here is the detail most comparison pages skip entirely. The BPC-157 sequence contains an Asp-Asp-Ala-Gly motif. Aspartyl residues followed by small residues are the classic hotspot for aspartimide formation during Fmoc synthesis under repeated piperidine deprotection. The aspartimide intermediate is −18 Da relative to the parent, and it hydrolyses to a mixture of α-aspartyl and β-isoaspartyl peptide.
The isoaspartyl form is mass-identical to the correct peptide. A clean ESI-MS spectrum showing 1419.5 Da does not rule it out. Only chromatographic resolution — or enzymatic/peptide-mapping work — separates them.
This changes what "MS-confirmed" is worth on a BPC-157 COA. It confirms gross identity. It does not confirm regiochemical integrity at the Asp-Gly site. A supplier running a shallow 20-minute gradient may co-elute the isomer inside the main peak and report 99%. A supplier running a shallower, longer gradient with a resolving column will report a lower number on the same material — and that lower number is the more honest one. Ask which. NAD+ has no analogous silent isomer problem; its principal degradation route (hydrolysis of the nicotinamide-ribose bond to nicotinamide, 122.12 Da, plus ADP-ribose, ~559.3 Da) produces species that are obvious by both mass and retention.
A vial labeled "10 mg BPC-157" at 99% HPLC purity does not contain 9.9 mg of peptide. Lyophilized TFA-salt peptides commonly carry 5–10% water by Karl Fischer and 5–20% TFA by mass, depending on how many acidic residues the sequence has and how the material was lyophilized. BPC-157 has three acidic side chains plus the N-terminus, so it binds counterion readily. Net peptide content on a real lot frequently lands in the 75–88% range even when HPLC purity is genuinely 98–99%.
On a molar basis:
If your calculations run on molarity and you skip net peptide content, your stated concentrations are wrong by an amount that varies lot to lot. NAD+ sold as the disodium salt (685.4 g/mol) rather than the free acid carries an analogous 3.3% mass correction that is easy to miss on a re-order when the form changes.
Catalog pricing in the research-use segment separates these materials sharply:
The per-gram spread between bulk NAD+ and small-vial BPC-157 exceeds 1,000×. That gap is not margin — it is manufacturing route. Fermentation and enzymatic synthesis scale; stepwise SPPS on a 15-mer does not, because yield compounds across every coupling and deprotection step.
Verification costs are worth budgeting separately, because they are fixed per lot and therefore hit small orders hardest:
Spending $300 to verify a $45 vial is economically absurd. Spending $300 to verify a lot you will draw from for eighteen months is cheap. Verification economics, not purity claims, should drive your lot sizing. Bulk lot pricing is on the wholesale page.
Lyophilized BPC-157 is the more forgiving solid. Sealed, desiccated, and held at −20 °C, peptide powders are routinely assigned 24–36 month retest intervals, and brief ambient excursions during transit are tolerable for the dry powder. The fragile state is solution, not powder.
NAD+ powder is hygroscopic and needs desiccation more urgently; typical assignment is 24 months at −20 °C, sealed. In aqueous solution NAD+ is notably base-labile — alkaline conditions destroy it quickly, and neutral solutions held at room temperature lose measurable assay within days. Aliquoting and freezing is standard practice, with vendor documentation commonly assigning about 1 month at −20 °C and 6–12 months at −80 °C for stocks. Repeated freeze-thaw is a bigger threat to NAD+ working stocks than to peptide powder.
Both should ship cold. Ask what the actual transit protocol is — gel packs versus dry ice, and how many hours of thermal mass are specified — rather than accepting "shipped cold" as an answer. Details are on the shipping page.
This is the part a catalog page will not tell you.
Do not buy either material as research-use grade if your work needs a certified reference standard. NAD+ exists as a pharmacopeial-grade reference material with full metrological traceability. If your method validation, calibration curve, or regulatory submission requires a CRM, buying an RUO lot to save money invalidates the work. The saving is $200 against a study that costs far more to repeat.
BPC-157 has no pharmacopeial monograph and no certified reference standard anywhere. There is no external anchor. Every identity claim traces back to the supplier's own instrument and the supplier's own integration parameters. If your protocol requires orthogonal traceability to an independent standard, BPC-157 cannot provide it, and no supplier — including this one — can change that fact.
Do not buy if you cannot maintain −20 °C storage. A freezer failure over a weekend converts both materials into unknowns. There is no way to establish afterward what fraction degraded, and a COA issued at manufacture says nothing about a lot after a thermal excursion.
Do not buy small lots for long studies. Consuming three separate BPC-157 lots across an eighteen-month study introduces lot-to-lot variability — different net peptide content, different impurity profiles, potentially different isomer burden — as an uncontrolled variable in your own data. Either buy a single lot sized for the whole study, or plan to bridge lots analytically. Bridging costs more than buying big.
Do not buy BPC-157 if you lack HPLC access and cannot budget third-party testing. Without either, you are accepting an unverifiable claim about a material with no external standard. That is a defensible position for a $45 exploratory purchase and an indefensible one for anything you intend to publish.
Do not buy GMP-grade expectations at RUO prices. Research-use material is not manufactured under GMP, is not sterile unless explicitly stated, and carries no suitability claim for any application beyond laboratory research. That scope is stated plainly on the research use only page, and it is a real constraint, not boilerplate.
Reconsider bulk NAD+ if your assay is enzymatic. Fermentation-grade material at $0.60 per gram may carry nicotinamide and ADP-ribose carryover that inhibit or interfere with cycling assays. The cheap lot can cost more in failed plates than the expensive one saves.
Generic questions get generic answers. These do not:
A supplier who answers the first question with the specific gradient conditions is running the method. A supplier who answers it with "we test every batch" is not. Comparative notes on how domestic synthesis houses document this are collected in best bpc 157 made in usa, and the broader vendor-evaluation framework sits in the library.
If the requirement is a well-characterized, inexpensive, spectrophotometrically verifiable cofactor with an established enzymatic cross-check, NAD+ is the mature material — cheap per gram, easy to confirm, base-labile in solution and hygroscopic as a solid, with those two failure modes fully documented and manageable.
If the requirement is a synthetic peptide, expect to pay 1,000× more per gram, expect the label mass to overstate the peptide mass by 12–25%, expect no certified reference standard to exist, and expect the most consequential impurity to be invisible to mass spectrometry. None of that makes the material unsuitable. It makes single-lot purchasing, documented net peptide content, and a resolving chromatographic method non-negotiable rather than optional.
Specific lot documentation, including chromatograms and retest dates, is available before purchase — request it through contact rather than after the vial arrives.
Supplied strictly for in-vitro laboratory research by qualified researchers and institutions. Not a drug, food, cosmetic or dietary supplement. Not for human or veterinary consumption. Not evaluated by the FDA.
Purity, identity and lot number, documented for the exact vial you receive.